Schedule 13G ownership disclosure
LYRA THERAPEUTICS INC
Common Stock, $0.001 par value per share (the "Shares") · CUSIP: 55234L105
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Citadel Advisors LLC
Shares: 0.00 · Class: 0.0%
- Citadel Advisors Holdings LP
Shares: 0.00 · Class: 0.0%
- Citadel GP LLC
Shares: 0.00 · Class: 0.0%
- Citadel Securities LLC
Shares: 21,083.00 · Class: 0.0%
- Citadel Securities Group LP
Shares: 21,083.00 · Class: 0.0%
- Citadel Securities GP LLC
Shares: 21,083.00 · Class: 0.0%
- Kenneth Griffin
Shares: 21,083.00 · Class: 0.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-014360
- Form type
- SCHEDULE 13G/A
- Filer
- CITADEL ADVISORS LLC
- CIK
- CIK 1423053
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership